<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04144270</url>
  </required_header>
  <id_info>
    <org_study_id>70298</org_study_id>
    <nct_id>NCT04144270</nct_id>
  </id_info>
  <brief_title>The Importance of Muscle Function in Patients With Disseminated Bladder Cancer</brief_title>
  <official_title>The Importance of Muscle Function in Patients With Disseminated Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beckett Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Onkologisk Forskningsfond</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates if reduced muscle mass and muscle function predispose to poor
      completion of oncological treatment in patients with bladder cancer (including cancer of the
      renal pelvis, ureter and urethra) and if muscle mass and muscle function change during
      oncological treatment in these patients. It also evaluates biomarkers for sarcopenia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 18, 2019</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Muscle mass</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>We will describe if muscle mass at baseline is correlated to completion of planned systemic oncological treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle strength</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>We will describe if muscle strength at baseline is correlated to completion of planned systemic oncological treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle mass changes during systemic oncological treatment</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>We will describe if muscle mass change during systemic oncological treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength changes during systemic oncological treatment</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>We will describe if muscle mass change during systemic oncological treatment</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Urinary Bladder Neoplasm</condition>
  <arm_group>
    <arm_group_label>Included patients</arm_group_label>
    <description>One-arm study. All included patients will have muscle mass and muscle function evaluated</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Evaluation of muscle mass and muscle function</intervention_name>
    <description>Included patients have their muscle mass and muscle function evaluated before start on and after completion of oncological treatment.</description>
    <arm_group_label>Included patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with localized cancer in the urinary tract undergoing neoadjuvant chemotherapy
        prior to radical cystektomy or patients with disseminated disease undergoing chemotherapy
        or immunotherapy. Patients are identified and included from Department of Oncology,
        Rigshospitalet, Copenhagen, Denmark.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Age ≥ 18 år

          -  Histologically verified cancer of the renal pelvis, ureter, bladder or urethra
             regardless of type of histology

          -  ECOG performance status 0 - 3

          -  Meet the requirements for receiving oncological treatment (neoadjuvant chemotherapy
             for localized disease, chemotherapy or immunotherapy for disseminated disease).

        Exclusion Criteria:

          -  Age &lt; 18
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lise Hoej Omland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lise Hoej Omland, MD</last_name>
    <phone>+45 35450782</phone>
    <email>lise.hoej.omland@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lise Hoej Omland, MD</last_name>
      <phone>+45 35450782</phone>
      <email>lise.hoej.omland@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Helle Pappot, Professor</last_name>
      <email>helle.pappot@regionh.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>October 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2019</study_first_posted>
  <last_update_submitted>November 18, 2019</last_update_submitted>
  <last_update_submitted_qc>November 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Lise Hoej Omland</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Urinary Bladder Neoplasm</keyword>
  <keyword>Urothelium Neoplasm</keyword>
  <keyword>Oncology</keyword>
  <keyword>Muscle function</keyword>
  <keyword>Sarcopenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

